BiotechTube

AZD6140 + Placebo to match AZD6140

Phase 1Completed
0 views this week 0 watching💤 Quiet
Interest: 29/100
29
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Gout

Conditions

Gout, Coronary Artery Disease

Trial Timeline

May 1, 2008 → Jul 1, 2008

NCT ID
NCT00738842

About AZD6140 + Placebo to match AZD6140

AZD6140 + Placebo to match AZD6140 is a phase 1 stage product being developed by AstraZeneca for Gout. The current trial status is completed. This product is registered under clinical trial identifier NCT00738842. Target conditions include Gout, Coronary Artery Disease.

What happened to similar drugs?

12 of 20 similar drugs in Gout were approved

Approved (12) Terminated (3) Active (7)
✅LumiracoxibNovartisApproved
✅Pegloticase + MethotrexateAmgenApproved
✅Pegloticase + Methotrexate (MTX)AmgenApproved
✅Pegloticase + Methotrexate (MTX) + Standard Gout Flare Prophylaxis + Infusion Reaction (IR) ProphylaxisAmgenApproved
✅Pegloticase + methotrexate + placebo + gout flare prophylaxis regimen + fexofenadine + acetaminophen + methylprednisoloneAmgenApproved
✅Etanercept + Triamcinolone AcetonideAmgenApproved
✅PegloticaseAmgenApproved

Hype Score Breakdown

Clinical
6
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT00738842Phase 1Completed

Competing Products

20 competing products in Gout

See all competitors
ProductCompanyStageHype Score
febuxostat + AllopurinolAstellas PharmaPhase 3
40
Dotinurad + FebuxostatEisaiPhase 3
40
BaricitinibEli LillyPhase 2
35
HR091506 tablets + placebo of febuxostat tablets + febuxostat tablets + placebo of HR091506 tabletsJiangsu Hengrui MedicinePhase 1
25
SHR4640 tablet + SHR4640 tablet + febuxostat tablet + SHR4640 placebo tabletJiangsu Hengrui MedicinePhase 2
31
repaglinide; midazolam; SHR4640 + repaglinide; midazolam; SHR4640; SHR4640 placebo + repaglinide; midazolam; SHR4640 placeboJiangsu Hengrui MedicinePhase 1
29
SHR4640 + placeboJiangsu Hengrui MedicinePhase 1
29
SHR4640 dose1 + SHR4640 dose2 + Placebo oral tablet + Allopurinol 300 MGJiangsu Hengrui MedicinePhase 3
40
Colchicine + Febuxostat + SHR4640Jiangsu Hengrui MedicinePhase 1
29
SHR4640 + AllopurinolJiangsu Hengrui MedicinePhase 3
40
SHR4640 ；Febuxostat + SHR4640 ; Febuxostat + SHR4640 + SHR4640 + FebuxostatJiangsu Hengrui MedicinePhase 2
42
SHR4640Jiangsu Hengrui MedicinePhase 1
25
HR091506 tablets + placebo of febuxostat tablets + febuxostat tablets + placebo of HR091506 tabletsJiangsu Hengrui MedicinePhase 3
47
HR091506 tablets + placebo of febuxostat tablets + febuxostat tablets + placebo of HR091506 tabletsJiangsu Hengrui MedicinePhase 3
40
SHR4640 + PlaceboJiangsu Hengrui MedicinePhase 1
29
Zurampic® + Control group: xanthine oxidase inhibitor monotherapyAstraZenecaPre-clinical
18
Risk of selected safety eventsAstraZenecaPre-clinical
26
RDEA3170 + Allopurinol + PlaceboAstraZenecaPhase 2
35
RDEA3170 + Febuxostat + BenzbromaroneAstraZenecaPhase 1/2
32
Canakinumab pre-filled syringe + Canakinumab lyophilized powder + Triamcinolone Acetonide + PlaceboNovartisPhase 3
40